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Abstract: Viral diseases affect hundreds of millions of people worldwide, and the few 
available drugs to treat these diseases often come with limitations. The key obstacle to the 
development of new antiviral agents is their delivery into infected cells in vi vo.  
Cell-penetrating peptides (CPPs) are short peptides that can cross the cellular lipid bilayer with 
the remarkable capability to shuttle conjugated cargoes into cells. CPPs have been successfully 
utilized to enhance the cellular uptake and intracellular trafficking of antiviral molecules, and 
thereby increase the inhibitory activity of potential antiviral proteins and oligonucleotide 
analogues, both in cultured cells and in animal models. This review will address the notable 
findings of these studies, highlighting some promising results and discussing the challenges 
CPP technology has to overcome for further clinical applications. 
Keywords: cell-penetrating peptide; antivirals; antisense; drug delivery 
 
1. Nature and Scope of the Challenges Presented by Viral Infections 
Viral diseases affect hundreds of millions of people worldwide, resulting in a devastating toll on human 
health and socio-economic development. Along with the emergence of newly-recognized human 
pathogens (the SARS coronavirus, the recent influenza viruses H5N1 and H1N1), the ever-increasing 
incidence of chronic viral infections caused by HIV and hepatitis B and C viruses continues to increase 
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the global burden of infectious diseases [1,2]. Vaccines have been developed for some of the most 
important viral pathogens. Although vaccines against HIV [3] and hepatitis C virus [4] are in clinical 
phases III and II respectively, there is still little prospect of effective vaccines against these agents. There 
are enormous challenges to the development of these vaccines, especially since millions of people are 
already chronically infected with these viruses, which would require therapeutic vaccines for control. 
These challenges emphasize the importance of chemotherapy to treat these viral infections [5]. There 
are around 40 antiviral compounds in clinical use targeting various viral diseases (over half of these drugs 
are being used in the treatment of patients with HIV infection) while there is no treatment for most acute 
infections, such as the ones that cause severe illnesses, including hemorrhagic fever, encephalitis, and 
even cancer [6–9]. Most of the available drugs are of limited efficacy and come with severe side effects [6]. 
Importantly, antiviral chemotherapy is plagued by the rapid development of drug resistance strains, 
resulting from the high rate of replication of viruses combined with the low fidelity with which they 
replicate their genomes [10]. 
In view of the modest existing drug arsenal, the continuing threat posed by viral pathogens urgently 
calls for the development of novel antiviral agents. As obligate intracellular parasites, viruses present 
formidable challenges to drug development, the biggest being the in vivo delivery of the antiviral drug into 
the infected cells, with minimum toxicity to the host cells [6]. 
2. The Advent of Cell-Penetrating Peptides 
Traditional antiviral therapy has relied on small molecules such as protease inhibitors or nucleotide 
analogues to inhibit viral enzymes. In the last decades, proteins and nucleic acid molecules have shown 
very promising antiviral properties. However, due to their physical properties, such as size or 
hydrophilicity, the cellular uptake of these molecules is strongly restricted. The inability of these 
molecules to cross the cell membrane to reach their intracellular target precludes further clinical 
application. The cellular delivery of these molecules has thus arisen as a cornerstone for therapeutic 
development. 
Current techniques for cellular delivery of antivirals include targeted liposomes in cell culture and in 
mice [11–14], receptor-mediated endocytosis through antibody binding in cell culture and in mice [15], 
retroviral vectors in cell culture [16], as well as adenoviruses in vaccine delivery [17]. However these 
techniques present certain limitations and concerns: low efficiency [11,15], immunogenicity [14,15], 
stability and rapid clearance in bloodstream [18] for liposomal reagents, and immunogenicity and viral 
integration on host gene expression for viral vectors [15,19]. 
A novel strategy to efficiently overcome the impermeable cell barrier came from the surprising 
findings in the late 1980s that certain naturally occurring short peptide sequences have the ability to enter 
cells when added to culture media. The tat peptide, derived from HIV-1 transcriptional activator protein 
(tat) [20,21], and penetratin, derived from Drosophila antennapedia (Antp) transcription protein [22], were 
the first cell-penetrating peptides (CPPs) to be described. Tat and penetratin have paved the way to the 
discovery of other naturally occurring CPPs such as the herpesvirus tegument protein VP22 [23,24] or the 
cell wall protein-derived peptide inv3 from Mycobacterium tuberculosis [25,26]. Chimaeric CPPs such as 
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transportan (a chimera of the neuropeptide galanin and the wasp venom toxin mastoparan) [27] and totally 
synthetic CPPs such as the model amphipathic peptide (MAP) [28] or arginine oligomers [29] have also 
been designed and are routinely used. The exact mechanism of cellular uptake is not clear and studies 
remain controversial. Current models include uptake through transient pore formation, caveolae, clathrin-
dependent endocytosis, and macropinocytosis. Recent data suggest endocytosis as the prevailing model 
for uptake, although several mechanisms may coexist and differ depending on CPPs [30,31]. 
What makes these peptides very attractive as a delivery system is their ability to promote intracellular 
uptake of conjugated cargoes [32]. CPPs have successfully improved the cellular uptake of various 
cargoes including proteins [26,33], nucleic acids (oligonucleotides [34,35], peptide-nucleic acids [36,37], 
siRNAs [38,39]), nanoparticules [40] and liposomes [41] in a wide range of cells: mainly in mammalian 
cells, but also in bacteria [37,42], yeasts [42] and protozoan parasites [43,44]. CPPs have proven to be 
very efficient in delivering molecules into cells that are refractory to transfection such as primary 
lymphocytes [45]. In 1999, Schwarze et a l. successfully delivered into all tissues in mice the 120-kDa  
tat-conjugated β-galactosidase protein, which retained its enzymatic activity [46]. Impressively, the 
conjugate had also crossed the blood-brain barrier and reached the brain tissues, which is usually restricted 
to small and highly lipophilic peptides. CPPs offer the opportunity to deliver therapeutic molecules that 
are 200 times larger than the current bioavailability size restriction [45]. CPP-mediated delivery of 
bioactive compounds into model organisms for cancer [47], cardiomyopathy [48], stroke [49], muscular 
dystrophy [50] and viral infections, support the strong therapeutic potential exerted by CPPs. Clinical 
trials are taking CPP-based drugs a step closer to therapeutic applications. An heptamer arginine-
conjugated cyclosporine A (Psorban) has entered phase II of a clinical trial for topical treatment of 
psoriasis [29,51]. The oligoarginine peptide allows the penetration of cyclosporine A into cells throughout 
the otherwise impermeable epidermis and dermis. 
This review will focus on studies that explored the use of CPPs to deliver antisense agents into virus-
infected cells and animal models (Table 1). 
Table 1. Antiviral agents successfully delivered into virus-infected cells via conjugation to 
CPPs. CPPs from conjugates which exhibited some antiviral activity are mentioned. R stands 
for arginine, X for 6-aminohexanoic acid, and B for β-alanine. 
Antiviral 
cargo 
Targeted virus 
Conjugated 
CPP 
Experimental 
systems 
Limitations – CPP 
composition requirements 
PMO 
RNA viruses 
West Nile virus [66,67] (RXR)4XB 
Cell culture 
Mouse 
Dose-dependent toxicity in 
cell culture and mice 
Japanese encephalitis 
virus [67] 
(RXR)4XB Cell culture  
St. Louis encephalitis 
virus [67] 
(RXR)4XB Cell culture  
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Dengue virus [68–70] 
(RXR)4XB 
R5F2R4C 
R9F2C 
Cell culture 
Mouse 
 
SARS coronavirus [71] 
R9F2C 
R5F2R4C 
Cell culture  
Mouse hepatitis virus 
 [59,63] 
R9F2C 
(RXR)4XB 
Cell culture 
Mouse 
PPMO toxicity in mice when 
treatment given after MHV 
challenge 
 
PPMO with higher number of 
arginine residues exhibit 
greater antiviral activity in 
cell culture 
 
PPMO with insertions of 6-
aminohexanoic acid offer 
greater protection in mouse 
Equine arteritis virus [72] R9F2C Cell culture  
Porcine reproductive and 
respiratory syndrome 
virus [73] 
R5F2R4C Cell culture  
Poliovirus 1 [75] 
R9F2C 
(RXR)4XB 
Cell culture 
Mouse 
in vitro toxicity when longer 
periods of treatment 
Human rhinovirus 14 
 [75] 
R9F2C 
(RXR)4XB 
Cell culture 
 
 
Coxsackievirus B2 
 [75] 
R9F2C 
(RXR)4XB 
Cell culture 
 
 
Coxsackievirus B3 
 [76] 
(RXR)4XB 
Cell culture 
Mouse 
 
Foot-and-mouth disease 
virus [74] 
R9F2C Cell culture  
Sindbis virus [77] R9F2C Cell culture  
Venezuelan equine 
encephalitis virus [77] 
(RXR)4XB 
Cell culture 
Mouse  
 
Ebola virus 
 [64,78] 
(RXR)4XB 
R9F2C 
(RX)n=2-8B 
(RB)8B 
Cell culture 
Mouse 
PPMO with insertions of 6-
aminohexanoic acid and 
higher number of arginine-6-
aminohexanoic repeats offer 
greater protection in mouse 
Respiratory syncytial 
virus [79] 
(RXR)4XB 
Cell culture 
Mouse 
Endosomal entrapment 
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Measles virus [80] (RXR)4XB Cell culture  
Influenza A virus [81–83] 
(RXR)4XB 
R5F2R4C 
Cell culture 
Mouse 
Higher doses of PPMO 
induced abnormal infiltration 
of mouse lungs by immune 
system cells  
DNA viruses 
Kaposi’s sarcoma-
associated herpesvirus 
[84,85] 
R5F2R4C 
(RXR)4XB 
Cell culture  
Herpesvirus type 1 
 [86] 
(RXR)4XB 
Cell culture 
Mouse 
 
PNA HIV-1 [91–95,99–101] 
Disulfide-linked: 
tat 
penetratin 
transportan 
transportan 21 
transportan 22 
R6-penetratin 
Stably-linked: 
tat 
transportan 
transportan 21 
Cell culture 
 
Some 
preliminary 
mouse studies 
for tat and 
penetratin 
conjugates 
Endosomal entrapment 
requiring lysosomotropic 
agents 
Nature of CPP and of CPP-
PNA linkage had an effect on 
conjugate activity 
 
Japanese encephalitis 
virus [96] 
tat Cell culture  
siRNA Hepatitis C virus [102] tat Cell culture  
 HIV-1 [15] 
nonamer arginine 
(9R) 
non-covalent 
binding 
Mouse   
Proteins HIV-1 [103–105] tat Cell culture  
 
Human papillomavirus 
type 18 [106] 
9R 
PTD4 
Cell culture 
Nature of CPP directly 
impacted the level of 
antiviral activity 
3. Delivery of Antisense Agents 
The past decade has witnessed the breakthrough of gene-silencing antisense agents including antisense 
oligonucleotides (AOS), AOS analogues, ribozymes, DNAzymes and the popular siRNAs. This novel 
approach is based on the discovery 30 years ago that nucleic acid molecules could be used to specifically 
target complementary viral nucleic acid sequences and inhibit viral replication [52,53]. With these new 
promising molecules comes the ability to simultaneously target multiple viral sequences, which would 
preclude the selection of drug resistance. 
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Figure 1. Mechanisms of antiviral activity exerted by CPP conjugates. These antiviral agents 
can target retroviruses, as shown for HIV, non-retroviral RNA viruses, as shown for the 
negative-sense RNA EBOV and HCV, and DNA viruses, as shown for HSV. Interference with 
viral RNA processing and translation further inhibits viral replication. CPP conjugates can also 
be designed to target virus-infected cells. CPP can also inactivate the virion and render cells 
resistant to infection, inhibiting cell infection. proCasp3 stands for pro-caspase 3; RT stands 
for reverse transcription; Tn stands for transportan. 
 
3.1. Delivery of Phosphorodiamidate Morpholino Oligomers (PMOs) 
So far, conjugation of CPPs to phosphorodiamidate morpholino oligomers (PMOs) has clearly been the 
most popular and most promising use of CPPs in antiviral development. PMOs are antisense DNA 
oligonucleotide analogues [54]. Their backbone is composed of morpholine rings joined by uncharged 
phosphodiamidate linkages, in place of the sugar and anionic phosphodiester linkage of DNA. They are 
typically synthesized as 20–25-base long oligomers. They offer great features for clinical applications: 
they are water-soluble, nuclease-resistant, and their uncharged backbone interacts weakly with serum and 
cellular proteins thereby reducing toxicity [55]. PMOs are mainly designed to interact with 5’ and 3’  
non-coding regions of the target mRNA, AUG-codon translation start-site region or splice junctions. They 
tat proCasp3
tatp27SJ
Interaction with HIV-1 
tat and cellular protein HIV transcription
Processing by 
HIV protease
Apoptosis
Nucleus
Interaction with 
viral and cell 
glycoproteins
Cell infection
tat
P7
transcription
translation
Θ
PMO
EBOV genomic RNAHCV genomic RNA
Cleavage by RISC
tat
siRNA
PNA
HSV virion
RT
HIV virion
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act through steric blockage of the complementary RNA sequences, precluding proper mRNA processing 
or translation and thus reducing target protein levels and viral replication (Figure 1). 
As PMOs do not efficiently enter cells on their own, investigators have been routinely arming them 
with CPPs to promote their uptake into virus-infected cells and enhance their antisense efficacy [56,57]. 
These peptide-conjugated PMOs are referred to as PPMOs in the literature. As highlighted by Moulton 
and Jiang [58], PMOs are particularly well-suited cargoes for CPPs as their uncharged components do not 
interact with the positively-charged carrier peptide thereby not interfering with its membrane binding 
properties. The first report of PPMO antiviral activity in 2004 [59] has fueled the increasing interest in 
PMO-technology to inhibit viral infections as witnessed by more than 20 in vitro and/or in vivo studies 
published on antiviral PPMOs within the last five years (Table 1). Studies on RNA viruses have been 
extensively reviewed by Stein [60] with the latest in vivo work discussed by Moulton and Jiang [58]. We 
will focus here on the overall findings in regards to the cell penetrating moiety of the conjugates, and we 
will then review the studies on targeting DNA viruses. 
3.1.1. Nature of Peptides Conjugated to PMOs 
Peptide-mediated PMO delivery has been the focus of intense efforts to identify active, stable, non 
toxic and endosomolytic CPPs, of which (RXR)4XB (also called P7; R = L-arginine, X = 6-aminohexanoic 
acid; B = β-alanine) has proven very successful [61,62]. In antiviral studies, PMOs have been covalently 
linked to various arginine-rich peptides, the most frequent being R9F2C (R = L-arginine;  
F = L-phenylalanine; C = L-cysteine), R5F2R4C (also called P4), and (RXR)4XB. Conjugation is mainly at 
the 5’-terminal end of the PMO. In studies comparing the activity of various CPPs against murine 
hepatitis virus (MHV) [63] and Ebola virus (EBOV) [64], arginine-rich peptides with insertions of  
6-aminohexanoic acid stood out for their in vi vo effectiveness. The higher the number of arginine-6-
aminohexanoic repeats, the higher were PMO antiviral effect on MHV in cell culture [63] and the protection 
against EBOV infection in mice [64]. These findings agree with the results from Amantana et a l. [57],  
Abes et al. [61] and Youngblood et al. [65], who also found that these residues increased serum stability 
and enhanced endosomal escape of the conjugates. Burrer et al. documented that the nature of the linker 
(XB or cysteine) did not affect PPMO in v itro effectiveness against MHV or cytotoxicity, although the 
insertion of β-alanine residues was reported to improve both serum and intracellular stability of PPMO 
conjugates [65]. 
3.1.2. PPMOs against RNA Viruses 
PPMO antiviral activity has mainly been exploited against a wide range of non-retroviral RNA viruses. 
In cell culture, PPMOs were tested against West Nile virus (WNV) [66,67], Japanese encephalitis virus [67], 
St. Louis encephalitis virus [67], dengue virus (DENV) [68–70], severe acute respiratory syndrome 
coronavirus (SARS-CoV) [71], MHV [59,63], equine arteritis virus [72], porcine reproductive and 
respiratory syndrome virus [73], foot-and-mouth disease virus [74], poliovirus 1 (PV1) [75], human 
rhinovirus 14 [75], coxsackievirus B2 [75], coxsackievirus B3 (CVB3) [76], Sindbis virus [77], Venezuelan 
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equine encephalitis virus (VEEV) [77], EBOV [64,78], respiratory syncytial virus (RSV) [79], measles 
virus [80], and influenza A virus (FLUAV) [81,82]. 
Cell culture assays consistently showed that PPMO readily entered infected cells and could specifically 
and strongly inhibit viral replication. Fluorescein-labeled PPMOs accumulated in the nucleus but were 
present throughout the cells [66,79]. Lai et al. [79] reported punctuate foci of signal in the cell cytoplasm 
which might be indicative of endosomal entrapment of PPMO. 
Many investigators identified potent PPMO activity in cell culture assays and went on to test their 
antiviral properties in murine experimental models. Most of the investigators explored both the 
prophylactic and therapeutic potential of PPMO and the best protection was usually achieved with  
pre-infection and post-infection PPMO treatments. PPMOs were shown to suppress viral replication, 
attenuate symptoms of disease in and/or increase survivorship of mice infected with WNV [67], 
DENV [70], MHV [63], PV1 [75], CVB3 [76], VEEV [77], EBOV [64,78], RSV [79], and FLUAV [82,83]. 
Some PPMOs demonstrated very profound and impressive antiviral effects. In particular, two 5-μg  
pre-infection doses of (RX8)B-conjugated PMOs completely protected mice against lethal challenge with 
EBOV [64,78]. Mice treated with 200-μg doses of a (RXR)4XB-conjugated PPMO given pre- and post-
infection survived VEEV lethal infection [77]. The authors found that over the 28-day period of 
monitoring, VEEV was undetectable in PPMO-treated mice brain, blood and peripheral tissues. 
3.1.3. PPMOs against DNA Viruses 
While PPMOs are being routinely tested against RNA viruses, there have only been a handful of 
studies documenting the use of PPMO technology against DNA viruses. The first report came from  
Zhang et a l. who were interested in blocking Kaposi’s sarcoma-associated herpesvirus (KSHV) lytic 
replication [84]. They explored the effects of the inhibition of the expression of KSHV latency-associated 
nuclear antigen (LANA) and replication and transcription activator (RTA), two factors involved in latency 
maintenance and in the switch to lytic phase, respectively. To do so, the investigators designed PMOs 
directed against LANA and RTA and covalently conjugated them at their 5’ terminal to R5F2R4C peptide. 
While fluorescein (Fl)-labeled PMOs entered cells poorly, Fl-PPMOs were efficiently taken up by  
BCBL-1 lymphocytes which, as emphasized by the authors, are difficult to efficiently transfect with 
common techniques such as lipofectamine. PPMOs could effectively inhibit RTA and LANA protein 
expression in cell culture. Treatment of KSHV-infected cells with RTA PPMO suppressed KSHV lytic 
replication. RTA knock down resulted in reduced levels of proteins expressed downstream of RTA. One 
of these downstream proteins is viral interleukin-6 (vIL-6) and is thought to be essential for the 
development of KSVH-associated diseases. In a subsequent study, Zhang et al. blocked the expression of 
vIL-6 with PPMOs. vIL-6 PMOs were covalently conjugated at their 5’ to (RXR)4XB or R5F2R4C. PPMO 
treatment inhibited vIL-6 expression, which in turn reduced human IL-6 level and KSHV yield, and 
reduced growth of treated cells [85].  
Moerdyk-Schauwecker et al.  tackled the reactivation of another DNA virus, the herpes simplex virus 
type 1 (HSV-1) [86]. They investigated the antiviral activities of five (RXR)4XB-conjugated PMOs 
directed against three HSV-1 immediate-early genes, ICP0, ICP4 and ICP27 crucial for HSV-1 
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replication. The most potent PPMOs designed against ICP0 or ICP27 strongly inhibited HSV-1 replication 
in cell culture by reducing viral protein expression (Figure 1). In particular, ICP0 PPMO was able to 
suppress the replication of several HSV-1 strains, including an acyclovir-resistant strain. The authors also 
tested ICP0 PPMO in a mouse model of ocular herpes infection. Topical application of 10 μg ICP0 PPMO 
to the eyes of HSV-1 infected mice inhibited virus replication in mouse eyes and reduced the incidence of 
eye disease by 37.5–50%, thereby preventing death associated with HSV-1 eye infection. To evaluate  
in vivo PPMO toxicity, the investigators applied 100 μg ICP0 PPMO (ten times the antiviral dose) daily to 
the eyes of uninfected mice. No gross or microscopic eye damage, no effect on body weight and 
temperature and no change of behavior were observed following the seven-day treatment. These results 
strengthen the potential of PPMOs as a treatment for recurring corneal disease from HSV-1 reactivation.  
3.1.4. Enhancement of PMO Antisense Activity 
Besides improving PMO cellular uptake, the CPP moiety was also shown to intensify PMO antisense 
activity against EBOV by 10- to 100-fold in cell-free translation assays [64]. These results are consistent 
with the findings of Nelson et a l. who showed that PPMOs exhibited antisense activity 3- to 25-fold 
higher than corresponding PMOs while bearing lower off-target effects [87]. The authors propose that the 
arginine-rich peptides enhance RNA-PMO binding affinity thereby increasing specific antisense activity.  
3.1.5. PPMO Toxicity 
PPMOs appear to be generally well tolerated by cultured cells and animal recipients. However, some 
studies reported toxicity in cell culture with increase of PPMO dose [66] or longer period of  
exposure [66,75], and in vivo  toxicity as the treatment dose increased, usually at doses higher than 
antiviral ones [67]. The peptide moiety of PPMOs seems to contribute to this toxicity. When Deas et al. 
tested both PMO and PPMO against WNV in mice, they found that mice could tolerate higher doses of 
PMO compared to PPMO (3 mg against 300 μg, respectively) [67]. Mice treated with high doses of 
PPMO would suffer from weight loss and develop abnormal behavior and smaller livers. Besides dose-
dependent toxicity, the schedule of treatment regimen may also affect PPMO toxicity: while Burrer et al. 
did not document any treatment-associated toxicity when PPMOs were administered to healthy mice, they 
observed significant toxicity when PPMO treatment was given after MHV challenge [63]. Lupfer et a l. 
reported abnormal infiltration of mouse lungs by immune system cells when PPMO targeting FLUAV was 
administered at higher doses [83]. The authors hypothesized that the arginine-rich CPP mimics the 
eosinophil major basic protein, also rich in arginine residues, in triggering the migration of  
inflammatory cells. 
3.1.6. PPMO vs. PMO in vivo Antiviral Efficacy 
There have been a few reports of PMO-mediated antiviral activity in animal models. How PMOs could 
successfully suppress viral replication in vivo without the help of CPPS is not understood. Warfield et al. 
reported the nearly complete protection of rhesus macaques against EBOV lethal infection using PMOs [88]. 
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PMOs were also reported to increase the survival of calicivirus-infected cats [89]. Studies have been done 
that directly compared PMO and PPMO antiviral activity in vivo. One study found that both PPMO- and 
PMO-treated mice survived EBOV lethal challenge (100% and 85% respectively, the difference being not 
statistically significant) [78]. However, other comparative reports clearly document that PPMO are far 
more effective than PMOs in mice. PPMOs offered 100% protection against EBOV infection at 5-μg and 
50-μg doses while PMOs gave only 15% protection at 50-μg doses [64]. PPMOs increased survival of 
DENV-infected mice up to eight days whereas PMOs did not provide any survival benefit [70]. PMOs 
could not protect mice against WNV infection while PPMOs, even at doses 10-fold lower, delayed clinical 
signs and increased WNV-infected mice survival by 60% [67]. The differential activities observed in 
EBOV studies may be explained by the fact that Swenson et a l. used the (RXR)4XB peptide while 
Enterlein et al. linked their PMO to the R9F2C peptide. 
3.2. Delivery of Peptide-Nucleic Acids (PNAs) 
Peptide-nucleic acids or PNAs are oligonucleotide analogues in which the sugar-phosphate backbone 
has been replaced with peptide bonds [90]. They are resistant to both nucleases and proteases. They are 
used as antisense molecules to specifically bind to their complementary DNA or RNA sequences, creating 
a structural hindrance and inhibiting viral transcription, translation and replication processes. 
3.2.1. Antiviral Activity of CPP-PNA Conjugates in Cultured Cells 
Reports of anti-HIV-1 PNA delivery via CPPs come from Pandey’s [91–94] and Gait’s [95] groups 
which have been working on antivirals targeting highly-conserved regulatory regions of the HIV-1 
genome critical for its replication and gene expression, such as the primer-binding site, the A-loop and the 
transactivation response element (TAR). In their studies, the authors designed PNAs directed against these 
regions to inhibit HIV-1 gene expression and replication (Figure 1). 
The poor cellular uptake of these uncharged compounds led Pandey and co-workers to covalently 
conjugate PNA at its 5' end to various cell-penetrating peptides, including transportan, tat and penetratin, 
via disulfide bridges [91–94]. Upon coupling to these carrier peptides, the PNA cargoes were rapidly 
taken up by different human cell types in culture. When added to culture medium, these anti-HIV-1  
PNA–CPP conjugates effectively inhibited HIV-1 replication, tat-dependent trans-activation and viral 
production by infected cells; no significant decrease was observed with the unconjugated PNA, 
emphasizing the great promise held by these conjugates as antiviral agents [91].  
Turner et al. also chose to enhance the cellular delivery and biological activity of PNA by covalently 
attaching them to CPPs [95]. They raised the more technical but nonetheless very important question of 
how the type of CPP and the way it is linked to the PNA affects the ability of the PNA to reach its cellular 
target. They conjugated the PNA to the CPP either via a stable polyether linker or through a cleavable 
disulfide bond and tested a range of CPPs. They could inhibit tat-dependent trans-activation in HeLa cells 
with disulfide-linked conjugates of PNA to transportan or to the chimeric peptide R6-penetratin  
(R = L-arginine). However, unlike what was reported by Tripathi et a l. [93], they found that tat and 
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penetratin conjugates failed to inhibit transcription. None of the conjugates carrying the stable polyether 
linker could elicit trans-activation inhibition. Interestingly, supplementation of cell medium with the 
lysosomotropic reagent chloroquine enhanced inhibitory activity of disulfide-linked conjugates and stably-
linked conjugates gained some inhibitory activity. Supported by confocal microscopy data on cell 
localization of conjugates, the authors argued that endosomal release is a limiting factor in conjugates 
efficiency: following cell uptake, CPP-PNA conjugates would be entrapped in endosomal or other 
membrane-bound cytosolic compartments and some of them would then be slowly released. Endosomal 
entrapment was also reported with PPMO conjugates [79]. However, this observation differs from 
Chaubey et al. conclusion of the conjugates not being taken up by the endocytic pathway as uptake was 
not affected by low temperature or phenylarsine oxide [92]. Turner et al. attempted to improve not only 
the cell delivery but also the endosomal release properties of CPPs to increase PNA antiviral activity [95]. 
As no effective therapy is currently available for treatment of JEV infection, Yoo et al. investigated the 
antiviral activity exerted by various PNAs directed against JEV RNA cis-acting elements [96]. All PNAs 
were conjugated to tat via an O-linker to promote efficient cellular uptake. Tat-PNAs successfully 
inhibited JEV proliferation in cell culture. JEV replication is thought to take place in specialized structures 
derived from host membranes harboring the viral RNA polymerase and host proteins involved in viral 
RNA replication [97]. This would mean that not only tat-PNA conjugates crossed the plasma membrane 
but they were also able to penetrate into the convoluted membrane system to interfere with  
viral replication. 
3.2.2. Preclinical Studies of CPP-PNA Conjugates in Mice 
To date, only few in vi vo studies have been reported with CPP-PNA conjugates [98]. In the field of 
antivirals, Pandey and colleagues have started preliminary toxicity, immunological and pharmacokinetic 
studies in mice for the anti-HIV-1 PNATAR-penetratin conjugate [99–101]. Chaubey et a l. reported the 
non-toxicity of the complex when administered at repeat doses ranging up to 100 mg/kg [99]. Mice which 
were given 100 mg/kg of the conjugate, a dose the authors highlight is far in excess of the expected 
therapeutic dose, suffered from diarrhea and reduced physical activity and from spleen, liver and kidney 
serotosis. However they recovered during the 60-day follow-up period with no irreversible organ  
damage reported. 
Upadhyay et a l. demonstrated that PNATAR-penetratin conjugate is moderately immunogenic mainly 
due to its penetratin moiety [100]. Cytokine secretion profiles of the lymph node cells showed elevated 
levels of proinflammatory cytokines, such as IL-2 and IL-12, which are known to promote proliferation of 
T lymphocytes and slow down the death of CD4+ T cells. The authors emphasize that these immunogenic 
properties of the conjugate could prove to be beneficial to the host. 
Ganguly et a l. studied the tissue distribution and clearance of 125I-labeled PNATAR and its penetratin 
and tat conjugates [101]. They reported the distribution of the conjugates throughout the mouse major 
internal organs when administered by oral route as well as their slow release and clearance from different 
organs. Surprisingly, unconjugated naked PNATAR displayed a similar tissue distribution and clearance 
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profile although the extent of its uptake was lower than its CPP conjugate. In vivo antiviral activity of 
PNATAR and its penetratin and tat conjugates needs to be assessed. 
3.3. Delivery of Small Interfering RNAs (siRNAs) 
The use of CPPs to deliver siRNAs into cells has rather been limited to date, even more so for antiviral 
siRNAs. Järver et al.  suggested that siRNAs could be less amenable to CPP delivery due to charge 
interactions between the peptide and the siRNA and inefficient endosomal escape of the conjugates [30]. 
To our knowledge, the only report of CPP-mediated delivery of antiviral siRNA is from Meng et al. who 
constructed a cell-permeable siRNA targeting hepatitis C virus 5’ untranslated region [102]. The siRNA 
was crosslinked at its 3’ end with the tat peptide. The authors reported the cellular uptake and antiviral 
effect of the CPP-siRNA as being as efficient as transfection with lipofectamine in Huh-7 cell culture. 
However, some cell types being refractory to lipofectamine transfection which can moreover be toxic  
in vivo, CPP-mediated delivery of siRNA is definitely worth investigating in other cell types and in animal 
models of viral infections. 
Although Kumar et al.  did not use CPP as a cell delivery system per se , it is noteworthy that they 
exploited its binding capability to polyanionic nucleic acids such as siRNAs [15]. The authors developed a 
novel method for systemic delivery of antiviral siRNAs into T cells in mice: they used an antibody to the 
CD7 receptor as their delivery system by receptor-mediated endocytosis. They bound the siRNA to the 
antibody through the positively charged nona-D-arginine (9R) peptide conjugated to its C-terminal via a 
disulfide bond. They successfully suppressed HIV-1 infection in a humanized mouse model using a 
cocktail of these siRNA complexes, inhibiting HIV-1 entry into target cells and its replication.  
4. Delivery of Antiviral Proteins 
The following studies have harnessed the carrier capability of the tat and 9R peptides to shuttle 
potential antiviral proteins into virus-infected cells. To our knowledge, the first report of the successful 
use of CPP to deliver potential antiviral agents into cells is by Vocero-Akbani et al. in 1999 [103]. In their 
elegant study, the authors took a novel approach to specifically kill HIV-infected cells thereby preventing 
the production of infectious virions. They engineered a zymogen form of the apoptosis-promoting enzyme 
caspase 3 that, upon entry into HIV-infected cells, would be processed into its active form by the HIV 
protease (Figure 1). To deliver this modified caspase-3 into Jurkat T cells, they armed the recombinant 
protein with the tat peptide at its N-terminal. The authors showed that they could transduce about 100% of 
cells in less than 20 min. Confocal analysis localized FITC-labeled TAT-caspase-3 to both cytoplasmic 
and nuclear compartments. While TAT-caspase-3 remained inactive in uninfected cells, its uptake resulted 
in massive apoptosis in HIV-infected Jurkat T cells. Although a very promising study, no further or 
follow-up investigations have been reported. 
Due to its ability to interact with cellular and viral proteins, p27SJ, a protein from the St John’s wort, 
has been put forward as a potential anti-HIV-1 molecule by Darbinian et a l. [104]. Recently, the 
investigators have used the tat peptide as part of a bi-directional protein transduction system where the 
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antiviral protein of interest, p27SJ, was expressed with tat at its C-terminal. Secreted into the cell medium, 
the fusion protein efficiently entered HIV-infected cells through a tat-mediated uptake and strongly 
inhibited HIV-1 transcription and replication (Figure 1). 
The tat peptide was also conjugated to peptide ligands impairing interactions between the HIV-1 
regulatory protein Rev and host cellular factors [105]. Following their tat-mediated cellular uptake into 
primary lymphocytes and macrophages, these inhibitory heptapeptides, expressed in fusion with 
stabilizing proteins, successfully suppressed HIV-1 replication, although at a concentration higher than 
those of currently used antiviral drugs. Along with a better design of the peptide ligand, conjugation to 
other CPPs may improve cellular uptake and therefore antiviral activity. 
In addition to targeting HIV-1, CPP-mediated protein delivery was further exploited to inhibit human 
papillomavirus type 18 (HPV-18) in cell culture [106]. Mino et al. delivered artificial zinc-finger proteins 
(AZPs) into cultured cells by expressing AZPs in fusion with the 9R peptide. These AZP-9R conjugates 
strongly inhibited HPV-18 replication to 3% at 250 nM while gene-delivered AZP only achieved 12% 
inhibition. PTD4 conjugates were also tested but proved to be less effective than AZPs fused to 9R. 
5. Antiviral Properties Exerted by CPPs Themselves 
While studying the delivery of anti-HSV-1 antivirals using a peptide derived from FGF4 signal 
peptide, Bultmann et al.  found that the peptide itself exerted antiviral activity [107]. This discovery led 
them to investigate the intrinsic antiviral properties of a range of peptides against HSV-1 infection in 
cultured cells. Tested peptides included EB (stands for entry blocker; it is a modified FGF4 signal 
peptide), tat, KLA (a synthetic amphipatic peptide), and HOM (derived from Drosophila antennapedia 
protein), and their modified peptides [107–109]. In particular, a tat peptide containing a cysteine residue at 
its C-terminal (tat-C) was shown to be able to inhibit infection in three ways: irreversibly inactivating 
virions exposed to tat-C prior to cell infection, blocking entry of cell-adsorbed viruses, and inducing a 
state of resistance to infection in cells pretreated with tat-C (Figure 1) [109]. Mechanisms of antiviral 
activities have not been determined yet but tat-C seems to act by inhibiting viral entry at the fusion step 
rather than at the virus attachment step. Virion inactivation may result from tat-C binding to sialic acids on 
the viral envelop glycoproteins. 
Along with the antiviral property of their anti-HIV-1 PNA-CPP complexes, Chaubey et a l. and  
Tripathi et a l. investigated the virucidal effect of their conjugates and their potential use as  
microbicide [92,94]. They showed that pre-incubation of HIV-1 virions with these molecules rendered 
them noninfectious and blocked further cell infection. Two hypotheses may explain these results (Figure 1). 
The conjugates may have been able to enter the virion particles and bind to the TAR region of the viral 
RNA. The PNA-CPP may also have altered or disrupted the viral envelope through the interaction of the 
CPP moiety with the viral lipid bilayer, thereby inhibiting host cell infection. The authors showed that 
brief exposure of virions to CPP-PNA conjugates blocked endogenous reverse transcription within virion 
particles, arguing in favor of a virucidal effect due to the PNA moiety interaction with the viral RNA. 
However, their work set the stage for exploring anti-HIV-1 activity displayed by CPPs on their own. 
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CPPs share structural similarities and membrane-binding properties with another class of peptides: the 
antimicrobial peptides (AMPs) [31]. AMPs are small peptides carrying basic and hydrophobic residues. 
They are found in all living organisms. Mainly produced by leukocytes and epithelial cells, they are major 
players in the innate immune response against infectious agents. Interestingly, AMPs have been put 
forward as one potential class of novel antivirals. Their antimicrobial activity has been reported against 
both enveloped and non-enveloped viruses, blocking viral infection in different ways [110]: they can 
directly inactivate the virion through disruption of its envelop or interaction with its glycoproteins; they 
can act on infected cells possibly through interactions with cell receptors resulting in alterations in cell-
signaling pathways required for virus replication; they can block the fusion of the viral membrane with the 
endosome of the host cell, thereby interfering with viral replication; finally, they can interact with and 
inhibit viral enzymes essential to the virus replication [111]. In view of the similarities between CPPs and 
AMPs and of the reports of anti-HSV-1 effects of some peptides, CPP’s potential intrinsic antiviral 
activity undoubtedly deserves further investigation.  
6. Conclusions 
The above reviewed studies contain a common message: CPP-conjugated antiviral agents hold great 
promise as novel preventive and therapeutic modalities against viral infections. The remarkable antiviral 
effects of PPMOs against lethal infections with EBOV, VEEV, FLUAV and DENV, and against the 
usually-lethal infections with PV1 and WNV, call for a wider use of CPPs in the delivery of antiviral 
drugs. CPP-conjugated antivirals also show promise in inhibiting the reactivation from latent infections of 
viruses such as HSV-1. Moreover, the assessment of CPP antiviral properties and the understanding of 
their molecular mechanisms could lead to the exploitation of these activities for the development of 
microbicides to inactivate virions after exposure. 
These CPP-antiviral studies illustrate the search for the “perfect” CPP-cargo couple, as CPP carrier 
efficiency is dependent on the nature of its cargo, affecting the antiviral activity. This is particularly true 
for PPMO research where much effort has been put towards developing highly active peptides to 
outperform the more traditionally used penetratin and tat peptides [61,62]. Improving CPP 
endosomolytical properties to intensify antiviral activity of the conjugated cargo has become a main focus, 
as the endosomal escape appears to be critical to antiviral activity [30].  
CPP should not only promote the cellular uptake of the cargo but also improve its intracellular 
trafficking to ensure that it reaches the appropriate cellular compartment. This aspect cannot be 
overlooked when designing antivirals as different viruses may carry their replication cycles in different 
subcellular locations such as the cytosol, the nucleus or in an intricate membrane system within the 
cytosol. The type of linkage between the CPP and the antiviral compound is of importance as for instance 
a disulphide bond would result in the rapid release of the cargo through the action of cytoplasm 
glutathione. Therefore the choice of CPP should not only be optimized to the cargo but should also be 
specific to the virus to ensure that the antiviral molecule efficiently reaches its viral target in the 
subcellular compartment. 
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Research on antiviral CPP-PNA, -siRNA and -protein conjugates, although encouraging, is still at its 
infancy and importantly needs validation in animal models. There is a need for improvement in the design 
of CPP to tackle the issue of in vi vo toxicity and thereby make the drug conjugates safer. As Stein 
highlights, even though PPMO dose regimens are shown to be nontoxic, it will be necessary to show that 
treatment with doses several times higher than the expected therapeutic dose is well tolerated [60]. It is 
noteworthy that all the PPMO studies were done in collaboration with a company specializing in RNA-
based drugs, AVI BioPharma Inc, which first developed the PMO and provided the PPMO compounds. Of 
all the CPP-antiviral investigations, PPMO studies are the ones that are at the most advanced stage, with 
several reports of use in animal models and directed against a wide range of viruses. The work on PPMO 
illustrates the successful collaboration between academia and industry.  
One recurring challenge in the global control of viral infections is the development of drug-resistant 
viral strains. It is very likely that escape mutants will arise during treatment, especially if long-term 
therapy is required. This issue can be overcome if treatment can be easily switched to different antisense 
molecules. The ease to synthesize a new CPP-PNA, CPP-siRNA or PPMO directed to the mutated 
sequence needs to be addressed. According to Stein, PPMO production is costly and complex [60]. Most 
investigators limited their in vivo studies to the most potent PPMO identified in cell culture. However, 
treatment with a combination of antisense molecules targeting multiple sequences in the viral genome 
should have a greater antiviral effect compared to a treatment with a single antisense molecule, and should 
prevent selection of escape variants. More studies with treatment with a cocktail of antivirals would be of 
critical relevance for further clinical applications. 
A number of CPPs are derived from viral proteins, such tat, VP22, and FHV. The role of these cell 
penetrating motifs during infection has yet to be elucidated but it is interesting to see that another obligate 
intracellular pathogen, Mycobacterium tuberculosis, also possesses a cell wall protein with such a peptide 
sequence [25]. CPPs represent an example of how understanding how pathogens interact with human host 
cells can lead to new ways to treat and prevent viral infections. 
References 
1. Haagmans, B.L.; Andeweg, A.C.; Osterhaus, A. The Application of Genomics to Emerging 
Zoonotic Viral Diseases. PLos Pathog. 2009, 5, 5. 
2. De Clercq, E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2004, 2, 704–720. 
3. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, 
N.; Namwat, C.; de Souza, M.; Adams, E.; Benenson, M.; Gurunathan, S.; Tartaglia, J.; McNeil, 
J.G.; Francis, D.P.; Stablein, D.; Birx, D.L.; Chunsuttiwat, S.; Khamboonruang, C.; Thongcharoen, 
P.; Robb, M.L.; Michael, N.L.; Kunasol, P.; Kim, J.H.; Investigators, M.-T. Vaccination with 
ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N. Engl. J . Med . 2009, 361,  
2209–2220. 
4. Wedemeyer, H.; Schuller, E.; Schlaphoff, V.; Stauber, R.E.; Wiegand, J.; Schiefke, I.; Firbas, C.; 
Jilma, B.; Thursz, M.; Zeuzem, S.; Hofmann, W.P.; Hinrichsen, H.; Tauber, E.; Manns, M.P.; Klade, 
Pharmaceuticals 2010, 3 
 
463
C.S. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis 
C. Vaccine 2009, 27, 5142–5151. 
5. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Dr ug Discov. 2007, 6,  
1001–1018. 
6. Dykxhoorn, D.M.; Lieberman, J. Silencing viral infection. PLOS Med. 2006, 3, 1000–1004. 
7. Blackburn, G.M.; Gait, M.J.; Loakes, D.; Williams, D.M. Nucleosides and Nucleotides. In Nucleic 
Acids in Chemistry and  Biolog y, 3rd Ed.; Royal Society of Chemistry: Cambridge, UK, 2006;  
pp. 77–142. 
8. Bharti, A.C.; Shukla, S.; Mahata, S.; Hedau, S.; Das, B.C. Anti-human papillomavirus therapeutics: 
Facts & future. Indian J. Med. Res. 2009, 130, 296–310. 
9. Chander, G.; Sulkowski, M.S.; Jenckes, M.W.; Torbenson, M.S.; Herlong, H.F.; Bass, E.B.; Gebo, 
K.A. Treatment of chronic hepatitis C: A systematic review. Hepatology 2002, 36, 135–144. 
10. McKeegan, K.S.; Borges-Walmsley, M.I.; Walmsley, A.R. Microbial and viral drug resistance 
mechanisms. Trends Microbiol. 2002, 10, S8–S14. 
11. Zhu, J.M.; Trang, P.; Kim, K.; Zhou, T.H.; Deng, H.Y.; Liu, F.Y. Effective inhibition of Rta 
expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. 
Proc. Natl. Acad. Sci. USA 2004, 101, 9073–9078. 
12. Duzgunes, N.; Simoes, S.; Slepushkin, V.; Pretzer, E.; Flasher, D.; Salem, II; Steffan, G.; Konopka, 
K.; De Lima, M.C.P. Delivery of antiviral agents in liposomes. Liposomes, Part E. Methods 
Enzymol. 2005, 391, 351–373. 
13. Clayton, R.; Ohagen, A.; Nicol, F.; Del Vecchio, A.M.; Jonckers, T.H.M.; Goethals, O.; Van Loock, 
M.; Michiels, L.; Grigsby, J.; Xu, Z.; Zhang, Y.P.; Gutshall, L.L.; Cunningham, M.; Jiang, H.; Bola, 
S.; Sarisky, R.T.; Hertogs, K. Sustained and specific in vi tro inhibition of HIV-1 replication by a 
protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res. 2009, 84, 142–149. 
14. Pan, W.H.; Xin, P.; Morrey, J.D.; Clawson, G.A. Self-processing ribozyme cassette: Utility against 
human papillomavirus 11 E6/E7 mRNA and hepatitis B virus. Mol. Ther. 2004, 9, 596–606. 
15. Kumar, P.; Ban, H.S.; Kim, S.S.; Wu, H.Q.; Pearson, T.; Greiner, D.L.; Laouar, A.; Yao, J.H.; 
Haridas, V.; Habiro, K.; Yang, Y.G.; Jeong, J.H.; Lee, K.Y.; Kim, Y.H.; Kim, S.W.; Peipp, M.; Fey, 
G.H.; Manjunath, N.; Shultz, L.D.; Lee, S.K.; Shankar, P. T cell-specific siRNA delivery suppresses 
HIV-1 infection in humanized mice. Cell 2008, 134, 577–586. 
16. Yu, X.K.; Trang, P.; Shah, S.; Atanasov, I.; Kim, Y.H.; Bai, Y.; Zhou, Z.H.; Liu, F.Y. Dissecting 
human cytomegalovirus gene function and capsid maturation by ribozyme targeting and electron 
cryomicroscopy. Proc. Natl. Acad. Sci. USA 2005, 102, 7103–7108. 
17. Shiver, J.W.; Emini, E.A. Recent advances in the development of HIV-1 vaccines using replication-
incompetent adenovirus vectors. Annu. Rev. Med. 2004, 55, 355–372. 
18. Fattal, E.; Couvreur, P.; Dubernet, C. "Smart" delivery of antisense oligonucleotides by anionic pH-
sensitive liposomes. Adv. Drug Delivery Rev. 2004, 56, 931–946. 
19. Sekaly, R.P. The failed HIV Merck vaccine study: A step back or a launching point for future 
vaccine development? J. Exp. Med. 2008, 205, 7–12. 
Pharmaceuticals 2010, 3 
 
464
20. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates 
through the plasma membrane and accumulates in the cell nucleus. J. Biol . Chem. 1997, 272, 
16010–16017. 
21. Frankel, A.D.; Pabo, C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. 
Cell 1988, 55, 1189–1193. 
22. Derossi, D.; Joliot, A.H.; Chassaing, G.; Prochiantz, A. The 3rd helix of the antennapedia 
homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 269, 10444–10450. 
23. Elliott, G.; Ohare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. 
Cell 1997, 88, 223–233. 
24. Phelan, A.; Elliott, G.; O'Hare, P. Intercellular delivery of functional p53 by the herpesvirus protein 
VP22. Nat. Biotechnol. 1998, 16, 440–443. 
25. Arruda, S.; Bomfim, G.; Knights, R.; Huimabyron, T.; Riley, L.W. Cloning of an Mycobacterium-
tuberculosis DNA fragment associated with entry and survival inside cells. Science 1993, 261, 
1454–1457. 
26. Lu, S.W.; Tager, L.A.; Chitale, S.; Riley, L.W. A cell-penetrating peptide derived from mammalian 
cell uptake protein of Mycobacterium tuberculosis. Anal. Biochem. 2006, 353, 7–14. 
27. Pooga, M.; Hallbrink, M.; Zorko, M.; Langel, U. Cell penetration by transportan. FASEB J. 1998, 
12, 67–77. 
28. Oehlke, J.; Scheller, A.; Wiesner, B.; Krause, E.; Beyermann, M.; Klauschenz, E.; Melzig, M.; 
Bienert, M. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to 
deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta Biomembr. 
1998, 1414, 127–139. 
29. Rothbard, J.B.; Garlington, S.; Lin, Q.; Kirschberg, T.; Kreider, E.; McGrane, P.L.; Wender, P.A.; 
Khavari, P.A. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and 
inhibition of inflammation. Nat. Med. 2000, 6, 1253–1257. 
30. Järver, P.; Langel, K.; El-Andaloussi, S.; Langel, U. Applications of cell-penetrating peptides in 
regulation of gene expression. Biochem. Soc. Trans. 2007, 35, 770–774. 
31. Henriques, S.T.; Melo, M.N.; Castanho, M. Cell-penetrating peptides and antimicrobial peptides: 
How different are they? Biochem. J. 2006, 399, 1–7. 
32. Gupta, B.; Levchenko, T.S.; Torchilin, V.P. Intracellular delivery of large molecules and small 
particles by cell-penetrating proteins and peptides. Adv. Drug Delivery Rev. 2005, 57, 637–651. 
33. Fawell, S.; Seery, J.; Daikh, Y.; Moore, C.; Chen, L.L.; Pepinsky, B.; Barsoum, J. Tat-mediated 
delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 1994, 91, 664–668. 
34. Morris, M.C.; Vidal, P.; Chaloin, L.; Heitz, F.; Divita, G. A new peptide vector for efficient delivery 
of oligonucleotides into mammalian cells. Nucleic Acids Res. 1997, 25, 2730–2736. 
35. Troy, C.M.; Derossi, D.; Prochiantz, A.; Greene, L.A.; Shelanski, M.L. Downregulation of Cu/Zn 
superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J. Ne urosci. 
1996, 16, 253–261. 
Pharmaceuticals 2010, 3 
 
465
36. Pooga, M.; Soomets, U.; Hallbrink, M.; Valkna, A.; Saar, K.; Rezaei, K.; Kahl, U.; Hao, J.X.; Xu, 
X.J.; Wiesenfeld-Hallin, Z.; Hokfelt, T.; Bartfai, T.; Langel, U. Cell penetrating PNA constructs 
regulate galanin receptor levels and modify pain transmission in vivo . Nat. Biot echnol. 1998, 16, 
857–861. 
37. Good, L.; Awasthi, S.K.; Dryselius, R.; Larsson, O.; Nielsen, P.E. Bactericidal antisense effects of 
peptide-PNA conjugates. Nat. Biotechnol. 2001, 19, 360–364. 
38. Meade, B.R.; Dowdy, S.F. Exogenous siRNA delivery using peptide transduction domains/cell 
penetrating peptides. Adv. Drug Delivery Rev. 2007, 59, 134–140. 
39. Eguchi, A.; Dowdy, S.F. siRNA delivery using peptide transduction domains. Trends Pharmacol. 
Sci. 2009, 30, 341–345. 
40. Lewin, M.; Carlesso, N.; Tung, C.H.; Tang, X.W.; Cory, D.; Scadden, D.T.; Weissleder, R. Tat 
peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. 
Nat. Biotechnol. 2000, 18, 410–414. 
41. Torchilin, V.P.; Rammohan, R.; Weissig, V.; Levchenko, T.S. TAT peptide on the surface of 
liposomes affords their efficient intracellular delivery even at low temperature and in the presence of 
metabolic inhibitors. Proc. Natl. Acad. Sci. USA 2001, 98, 8786–8791. 
42. Rajarao, G.K.; Nekhotiaeva, N.; Good, L. Peptide-mediated delivery of green fluorescent protein 
into yeasts and bacteria. FEMS Microbiol. Lett. 2002, 215, 267–272. 
43. Corradin, S.; Ransijn, A.; Corradin, G.; Bouvier, J.; Delgado, M.B.; Fernandez-Carneado, J.; 
Mottram, J.C.; Vergeres, G.; Mauel, J. Novel peptide inhibitors of Leishmania gp63 based on the 
cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein. Biochem. 
J. 2002, 367, 761–769. 
44. Lee, H.; Jefferies, R.; Watt, P.; Hopkins, R.; Sotzik, F.; Reid, S.; Armson, A.; Boxell, A.; Ryan, U. 
In vi tro analysis of the TAT protein transduction domain as a drug delivery vehicle in protozoan 
parasites. Exp. Parasitol. 2008, 118, 303–307. 
45. Schwarze, S.R.; Hruska, K.A.; Dowdy, S.F. Protein transduction: Unrestricted delivery into all 
cells? Trends Cell Biol. 2000, 10, 290–295. 
46. Schwarze, S.R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S.F., In vivo protein transduction: Delivery of 
a biologically active protein into the mouse. Science 1999, 285, 1569–1572. 
47. Harada, H.; Hiraoka, M.; Kizaka-Kondoh, S. Antitumor effect of TAT-oxygen-dependent 
degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. 
Cancer Res. 2002, 62, 2013–2018. 
48. Bian, J.; Popovic, Z.B.; Benejam, C.; Kiedrowski, M.; Rodriguez, L.L.; Penn, M.S. Effect of cell-
based intercellular delivery of transcription factor GATA4 on ischemic cardiomyopathy. Circ. Res. 
2007, 100, 1626–1633. 
49. Cao, G.D.; Pei, W.; Ge, H.L.; Liang, Q.H.; Luo, Y.M.; Sharp, F.R.; Lu, A.G.; Ran, R.Q.; Graham, 
S.H.; Chen, J. In vivo  delivery of a Bcl-xL fusion protein containing the TAT protein transduction 
domain protects against ischemic brain injury and neuronal apoptosis. J. Ne urosci. 2002, 22,  
5423–5431. 
Pharmaceuticals 2010, 3 
 
466
50. Jearawiriyapaisarn, N.; Moulton, H.M.; Buckley, B.; Roberts, J.; Sazani, P.; Fucharoen, S.; Iversen, 
P.L.; Kole, R. Sustained dystrophin expression induced by peptide-conjugated morpholino 
oligomers in the muscles of mdx mice. Mol. Ther. 2008, 16, 1624–1629. 
51. Price, V.H. Therapy of alopecia areata: On the cusp and in the future. J. Invest. Dermat. Symposium 
Proc. 2003, 8, 207–211. 
52. Stephenson, M.L.; Zamecnik, P.C. Inhibition of Rous-sarcoma viral-RNA translation by a specific 
oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA 1978, 75, 285–288. 
53. Zamecnik, P.C.; Stephenson, M.L. Inhibition of Rous-sarcoma virus-replication and cell 
transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 1978, 75, 280–284. 
54. Summerton, J.; Weller, D. Antisense properties of morpholino oligomers. Nucleosides Nucleotides 
1997, 16, 889–898. 
55. Summerton, J.E. Morpholino, siRNA, and S-DNA compared: Impact of structure and mechanism of 
action on off-target effects and sequence specificity. Curr. Top. Med. Chem. 2007, 7, 651–660. 
56. Moulton, H.M.; Nelson, M.H.; Hatlevig, S.A.; Reddy, M.T.; Iversen, P.L. Cellular uptake of 
antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjugate Chem. 2004, 15, 
290–299. 
57. Amantana, A.; Moulton, H.M.; Cate, M.L.; Reddy, M.T.; Whitehead, T.; Hassinger, J.N.; 
Youngblood, D.S.; Iversen, P.L. Pharmacokinetics, biodistribution, stability and toxicity of a cell-
penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 2007, 18, 1325–1331. 
58. Moulton, J.D.; Jiang, S. Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos. 
Molecules 2009, 14, 1304–1323. 
59. Neuman, B.W.; Stein, D.A.; Kroeker, A.D.; Paulino, A.D.; Moulton, H.M.; Iversen, P.L.; 
Buchmeier, M.J. Antisense morpholino-oligomers directed against the 5' end of the genome inhibit 
coronavirus proliferation and growth. J. Virol. 2004, 78, 5891–5899. 
60. Stein, D.A. Inhibition of RNA Virus Infections with Peptide-Conjugated Morpholino Oligomers. 
Curr. Pharm. Des. 2008, 14, 2619–2634. 
61. Abes, S.; Moulton, H.M.; Clair, P.; Prevot, P.; Youngblood, D.S.; Wu, R.P.; Iversen, P.L.; Lebleu, 
B. Vectorization of morpholino oligomers by the (R-Ahx-R)(4) peptide allows efficient splicing 
correction in the absence of endosomolytic agents. J. Control. Release 2006, 116, 304–313. 
62. Abes, R.; Moulton, H.M.; Clair, P.; Yang, S.T.; Abes, S.; Melikov, K.; Prevot, P.; Youngblood, 
D.S.; Iversen, P.L.; Chernomordik, L.V.; Lebleu, B. Delivery of steric block morpholino oligomers 
by (R-X-R)(4) peptides: Structure-activity studies. Nucleic Acids Res. 2008, 36, 6343–6354. 
63. Burrer, R.; Neuman, B.W.; Ting, J.P.C.; Stein, D.A.; Moulton, H.M.; Iversen, P.L.; Kuhn, P.; 
Buchmeier, M.J. Antiviral effects of antisense morpholino oligomers in murine coronavirus 
infection models. J. Virol. 2007, 81, 5637–5648. 
64. Swenson, D.L.; Warfield, K.L.; Warren, T.K.; Lovejoy, C.; Hassinger, J.N.; Ruthel, G.; Blouch, 
R.E.; Moulton, H.M.; Weller, D.D.; Iversen, P.L.; Bavari, S. Chemical modifications of antisense 
morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Age nts 
Chemother. 2009, 53, 2089–2099. 
Pharmaceuticals 2010, 3 
 
467
65. Youngblood, D.S.; Hatlevig, S.A.; Hassinger, J.N.; Iversen, P.L.; Moulton, H.M. Stability of cell-
penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjugate 
Chem. 2007, 18, 50–60. 
66. Deas, T.S.; Binduga-Gajewska, I.; Tilgner, M.; Ren, P.; Stein, D.A.; Moulton, H.M.; Iversen, P.L.; 
Kauffman, E.B.; Kramer, L.D.; Shi, P.Y. Inhibition of flavivirus infections by antisense oligorners 
specifically suppressing viral translation and RNA replication. J. Virol. 2005, 79, 4599–4609. 
67. Deas, T.S.; Bennett, C.J.; Jones, S.A.; Tilgner, M.; Ren, P.; Behr, M.J.; Stein, D.A.; Iversen, P.L.; 
Kramer, L.D.; Bernard, K.A.; Shi, P.Y. In vit ro resistance selection and in v ivo efficacy of 
morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 2007, 51,  
2470–2482. 
68. Kinney, R.; Huang, C.; Rose, B.; Kroeker, A.; Iversen, P.; Stein, D. Inhibition of Dengue virus 
serotypes 1-4 in cell culture with morpholino oligomers. Antiviral Res. 2005, 65, A87–A87. 
69. Holden, K.L.; Stein, D.A.; Pierson, T.C.; Ahmed, A.A.; Clyde, K.; Iversen, P.L.; Harris, E. 
Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the 
top of the terminal 3 ' stem-loop structure. Virology 2006, 344, 439–452. 
70. Stein, D.A.; Huang, C.Y.H.; Silengo, S.; Amantana, A.; Crumley, S.; Blouch, R.E.; Iversen, P.L.; 
Kinney, R.M. Treatment of AG129 mice with antisense morpholino oligomers increases survival 
time following challenge with dengue 2 virus. J. Antimicrob. Chemother. 2008, 62, 555–565. 
71. Neuman, B.W.; Stein, D.A.; Kroeker, A.D.; Churchill, M.J.; Kim, A.M.; Kuhn, P.; Dawson, P.; 
Moulton, H.M.; Bestwick, R.K.; Iversen, P.L.; Buchmeier, M.J. Inhibition, escape, and attenuated 
growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino 
oligomers. J. Virol. 2005, 79, 9665–9676. 
72. van den Born, E.; Stein, D.A.; Iversen, P.L.; Snijder, E.J. Antiviral activity of morpholino oligomers 
designed to block various aspects of Equine arteritis virus amplification in cell culture. J. Gen. Virol. 
2005, 86, 3081–3090. 
73. Zhang, Y.J.; Stein, D.A.; Fan, S.M.; Wang, K.Y.; Kroeker, A.D.; Meng, X.J.; Iversen, P.L.; Matson, 
D.O. Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino 
antisense oligomers. Vet. Microbiol. 2006, 117, 117–129. 
74. Vagnozzi, A.; Stein, D.A.; Iversen, P.L.; Rieder, E. Inhibition of foot-and-mouth disease virus 
infections in cell cultures with antisense morpholino oligorners. J. Virol. 2007, 81, 11669–11680. 
75. Stone, J.K.; Rijnbrand, R.; Stein, D.A.; Ma, Y.H.; Yang, Y.; Iversen, P.L.; Andino, R. A morpholino 
oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple 
species of picornavirus. Antimicrob. Agents Chemother. 2008, 52, 1970–1981. 
76. Yuan, J.; Stein, D.A.; Lim, T.; Qiu, D.X.; Coughlin, S.; Liu, Z.; Wang, Y.J.; Blouch, R.; Moulton, 
H.M.; Iversen, P.L.; Yang, D.C. Inhibition of coxsackievirus B3 in cell cultures and in mice by 
peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J. Virol. 2006, 
80, 11510–11519. 
Pharmaceuticals 2010, 3 
 
468
77. Paessler, S.; Rijnbrand, R.; Stein, D.A.; Ni, H.L.; Yun, N.E.; Dziuba, N.; Borisevich, V.; Seregin, 
A.; Ma, Y.H.; Blouch, R.; Iversen, P.L.; Zacks, M.A. Inhibition of alphavirus infection in cell 
culture and in mice with antisense morpholino oligomers. Virology 2008, 376, 357–370. 
78. Enterlein, S.; Warfield, K.L.; Swenson, D.L.; Stein, D.A.; Smith, J.L.; Gamble, C.S.; Kroeker, A.D.; 
Iversen, P.L.; Bavari, S.; Muhlberger, E. VP35 knockdown inhibits Ebola virus amplification and 
protects against lethal infection in mice. Antimicrob. Agents Chemother. 2006, 50, 984–993. 
79. Lai, S.H.; Stein, D.A.; Guerrero-Plata, A.; Liao, S.L.; Ivanciuc, T.; Hong, C.; Iversen, P.L.; Casola, 
A.; Garofalo, R.P. Inhibition of respiratory syncytial virus infections with morpholino oligomers in 
cell cultures and in mice. Mol. Ther. 2008, 16, 1120–1128. 
80. Sleeman, K.; Stein, D.A.; Tamin, A.; Reddish, M.; Iversen, P.L.; Rota, P.A. Inhibition of measles 
virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Res. 2009, 140, 
49–56. 
81. Ge, Q.; Pastey, M.; Kobasa, D.; Puthavathana, P.; Lupfer, C.; Bestwick, R.K.; Iversen, P.L.; Chen, 
J.; Stein, D.A. Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino 
oligomers. Antimicrob. Agents Chemother. 2006, 50, 3724–3733. 
82. Gabriel, G.; Nordmann, A.; Stein, D.A.; Iversen, P.L.; Klenk, H.D. Morpholino oligomers targeting 
the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A 
H7N7 virus. J. Gen. Virol. 2008, 89, 939–948. 
83. Lupfer, C.; Stein, D.A.; Mourich, D.V.; Tepper, S.E.; Iversen, P.L.; Pastey, M. Inhibition of 
influenza A H3N8 virus infections in mice by morpholino oligomers. Arch. V irol. 2008, 153,  
929–937. 
84. Zhang, Y.J.; Wang, K.Y.; Stein, D.A.; Patel, D.; Watkins, R.; Moulton, H.M.; Iversen, P.L.; Matson, 
D.O. Inhibition of replication and transcription activator and latency-associated nuclear antigen of 
Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Res. 2007, 73, 12–23. 
85. Zhang, Y.J.; Bonaparte, R.S.; Patel, D.; Stein, D.A.; Iversen, P.L. Blockade of viral interleukin-6 
expression of Kaposi's sarcoma-associated herpesvirus. Mol. Cancer Ther. 2008, 7, 712–720. 
86. Moerdyk-Schauwecker, M.; Stein, D.A.; Eide, K.; Blouch, R.E.; Bildfell, R.; Iversen, P.; Jin, L. 
Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27. 
Antiviral Res. 2009, 84, 131–141. 
87. Nelson, M.H.; Stein, D.A.; Kroeker, A.D.; Hatlevig, S.A.; Iversen, P.L.; Moulton, H.M. Arginine-
rich peptide conjugation to morpholino oligomers: Effects on antisense activity and specificity. 
Bioconjug. Chem. 2005, 16, 959–966. 
88. Warfield, K.L.; Swenson, D.L.; Olinger, G.G.; Nichols, D.K.; Pratt, W.D.; Blouch, R.; Stein, D.A.; 
Aman, M.J.; Iversen, P.L.; Bavari, S. Gene-specific countermeasures against Ebola virus based on 
antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006, 2, 5–13. 
89. Smith, A.W.; Iversen, P.L.; O'Hanley, P.D.; Skilling, D.E.; Christensen, J.R.; Weaver, S.S.; 
Longley, K.; Stone, M.A.; Poet, S.E.; Matson, D.O. Virus-specific antiviral treatment for controlling 
severe and fatal outbreaks of feline calicivirus infection. Am. J. Vet. Res. 2008, 69, 23–32. 
Pharmaceuticals 2010, 3 
 
469
90. Buchardt, O.; Egholm, M.; Berg, R.H.; Nielsen, P.E. Peptide Nucleic-Acids and Their Potential 
Applications in Biotechnology. Trends Biotechnol. 1993, 11, 384–386. 
91. Kaushik, N.; Basu, A.; Palumbo, P.; Myers, R.L.; Pandey, V.N. Anti-TAR polyamide nucleotide 
analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus 
type 1 production. J. Virol. 2002, 76, 3881–3891. 
92. Chaubey, B.; Tripathi, S.; Ganguly, S.; Harris, D.; Casale, R.A.; Pandey, V.N. A PNA-transportan 
conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal 
properties. Virology 2005, 331, 418–428. 
93. Tripathi, S.; Chaubey, B.; Ganguly, S.; Harris, D.; Casale, R.A.; Pandey, V.N. Anti-HIV-1 activity 
of anti-TAR polyamide nucleic acid coniugated with various membrane transducing peptides. 
Nucleic Acids Res. 2005, 33, 4345–4356. 
94. Tripathi, S.; Chaubey, B.; Barton, B.E.; Pandey, V.N. Anti HIV-1 virucidal activity of polyamide 
nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 
genome. Virology 2007, 363, 91–103. 
95. Turner, J.J.; Ivanova, G.D.; Verbeure, B.; Williams, D.; Arzumanov, A.A.; Abes, S.; Lebleu, B.; 
Gait, M.J. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 
Tat-dependent trans-activation in cells. Nucleic Acids Res. 2005, 33, 6837–6849. 
96. Yoo, J.S.; Kim, C.M.; Kim, J.H.; Kim, J.Y.; Oh, J.W. Inhibition of Japanese encephalitis virus 
replication by peptide nucleic acids targeting cis-acting elements on the plus- and minus-strands of 
viral RNA. Antiviral Res. 2009, 82, 122–133. 
97. Uchil, P.D.; Satchidanandam, V. Architecture of the flaviviral replication complex - Protease, 
nuclease, and detergents reveal encasement within double-layered membrane compartments. J. Biol. 
Chem. 2003, 278, 24388–24398. 
98. Lebleu, B.; Moulton, H.M.; Abes, R.; Ivanova, G.D.; Abes, S.; Stein, D.A.; Iversen, P.L.; 
Arzumanov, A.A.; Gait, M.J. Cell penetrating peptide conjugates of steric block oligonucleotides. 
Adv. Drug Delivery Rev. 2008, 60, 517–529. 
99. Chaubey, B.; Tripathi, S.; Pandey, V.N. Single acute-dose and repeat-doses toxicity of anti-HIV-1 
PNA(TAR)-penetratin conjugate after intraperitoneal administration to mice. Oligonucleotides 2008, 
18, 9–20. 
100. Upadhyay, A.; Ponzio, N.M.; Pandey, V.N. Immunological Response to Peptide Nucleic Acid and 
its Peptide Conjugate Targeted to Transactivation Response (TAR) Region of HIV-1 RNA Genome. 
Oligonucleotides 2008, 18, 329–335. 
101. Ganguly, S.; Chaubey, B.; Tripathi, S.; Upadhyay, A.; Neti, P.; Howell, R.W.; Pandey, V.N. 
Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted 
against HIV-1 transactivation response element. Oligonucleotides 2008, 18, 277–286. 
102. Meng, S.; Wei, B.J.; Xu, R.H.; Zhang, K.; Wang, L.N.; Zhang, R.; Li, J.M. TAT Peptides Mediated 
Small Interfering RNA Delivery to Huh-7 Cells and Efficiently Inhibited Hepatitis C Virus RNA 
Replication. Intervirology 2009, 52, 135–140. 
Pharmaceuticals 2010, 3 
 
470
103. Vocero-Akbani, A.M.; Vander Heyden, N.; Lissy, N.A.; Ratner, L.; Dowdy, S.F. Killing HIV-
infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat. Med. 1999, 5, 
29–33. 
104. Darbinian, N.; Popov, Y.; Khaliji, K.; Amini, S. Creation of a bi-directional protein transduction 
system for suppression of HIV-1 expression by p27SJ. Antiviral Res. 2008, 79, 136–141. 
105. Roisin, A.; Robin, J.P.; Dereuddre-Bosquet, N.; Vitte, A.L.; Dormont, D.; Clayette, P.; Jalinot, P. 
Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev. J. Biol. Chem. 2004, 279, 
9208–9214. 
106. Mino, T.; Mori, T.; Aoyama, Y.; Sera, T. Cell-permeable artificial zinc-finger proteins as potent 
antiviral drugs for human papillomaviruses. Arch. Virol. 2008, 153, 1291–1298. 
107. Bultmann, H.; Busse, J.S.; Brandt, C.R. Modified FGF4 signal peptide inhibits entry of herpes 
simplex virus type 1. J. Virol. 2001, 75, 2634–2645. 
108. Bultmann, H.; Brandt, C.R. Peptides containing membrane-transiting motifs inhibit virus entry.  
J. Biol. Chem. 2002, 277, 36018–36023. 
109. Bultmann, H.; Teuton, J.; Brandt, C.R. Addition of a C-terminal cysteine improves the anti-herpes 
simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT 
protein transduction domain. Antimicrob. Agents Chemother. 2007, 51, 1596–1607. 
110. Klotman, M.E.; Chang, T.L. Defensins in innate antiviral immunity. Nat. Rev. Immun ol. 2006, 6, 
447–456. 
111. Krajewski, K.; Marchand, C.; Long, Y.Q.; Pommier, Y.; Roller, P.P. Synthesis and HIV-1 integrase 
inhibitory activity of dimeric and tetrameric analogs of indolicidin. Bioorg. Med. Chem. Lett. 2004, 
14, 5595–5598. 
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This 
article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/3.0/). 
